Geneos Wealth Management Inc. Decreases Holdings in Repligen Co. (NASDAQ:RGEN)

Geneos Wealth Management Inc. reduced its stake in Repligen Co. (NASDAQ:RGEN) by 44.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 160 shares of the biotechnology company’s stock after selling 129 shares during the period. Geneos Wealth Management Inc.’s holdings in Repligen were worth $29,000 at the end of the most recent reporting period.

Other large investors have also bought and sold shares of the company. Fortis Capital Advisors LLC purchased a new position in Repligen in the 4th quarter worth approximately $35,000. Park Place Capital Corp increased its stake in shares of Repligen by 90.2% during the third quarter. Park Place Capital Corp now owns 253 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 120 shares during the period. Signaturefd LLC increased its stake in shares of Repligen by 44.1% during the third quarter. Signaturefd LLC now owns 281 shares of the biotechnology company’s stock valued at $45,000 after buying an additional 86 shares during the period. International Assets Investment Management LLC purchased a new position in shares of Repligen during the third quarter valued at approximately $51,000. Finally, Milestone Investment Advisors LLC purchased a new position in shares of Repligen during the third quarter valued at approximately $61,000. 97.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on RGEN. JPMorgan Chase & Co. boosted their target price on Repligen from $170.00 to $210.00 and gave the company an “overweight” rating in a research note on Wednesday, December 20th. Stifel Nicolaus boosted their target price on Repligen from $165.00 to $207.00 and gave the company a “buy” rating in a research note on Thursday, February 22nd. Finally, KeyCorp boosted their target price on Repligen from $210.00 to $220.00 and gave the company an “overweight” rating in a research note on Thursday, February 15th. One analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $196.70.

Repligen Trading Down 1.9 %

NASDAQ RGEN opened at $160.98 on Thursday. The company has a quick ratio of 5.75, a current ratio of 7.02 and a debt-to-equity ratio of 0.26. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The firm has a market capitalization of $8.99 billion, a PE ratio of 223.59, a P/E/G ratio of 5.38 and a beta of 1.02. The stock’s 50 day moving average is $190.84 and its 200 day moving average is $173.29.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Wednesday, February 21st. The biotechnology company reported $0.33 EPS for the quarter, meeting analysts’ consensus estimates of $0.33. The company had revenue of $155.74 million during the quarter, compared to analysts’ expectations of $155.38 million. Repligen had a return on equity of 5.00% and a net margin of 6.51%. Repligen’s revenue for the quarter was down 16.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.68 earnings per share. Research analysts forecast that Repligen Co. will post 1.46 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. In other Repligen news, CEO Anthony Hunt sold 16,707 shares of the company’s stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $197.44, for a total value of $3,298,630.08. Following the completion of the sale, the chief executive officer now owns 185,249 shares in the company, valued at $36,575,562.56. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, COO James Bylund sold 4,373 shares of the company’s stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $198.08, for a total value of $866,203.84. Following the completion of the sale, the chief operating officer now owns 14,135 shares of the company’s stock, valued at approximately $2,799,860.80. The disclosure for this sale can be found here. Insiders sold a total of 25,597 shares of company stock worth $5,039,532 over the last quarter. 1.20% of the stock is currently owned by corporate insiders.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.